New research from Intermountain Health in Salt Lake City highlights a concerning link between peripheral arterial disease (PAD) and atrial fibrillation (AFib). Patients diagnosed with both conditions face a significantly elevated risk of major adverse cardiovascular events (MACE). The study, which analyzed long-term data from patients at Intermountain Health, revealed that approximately one in four individuals with PAD also suffer from AFib, a combination that researchers argue is more common than previously recognized.
The findings indicate that the presence of AFib nearly doubles the risk of serious cardiovascular events when compared to patients with PAD alone. AFib is the most prevalent type of cardiac arrhythmia, characterized by an irregular heartbeat that can lead to rapid heart rates. Symptoms may include palpitations, fatigue, and shortness of breath, resulting from a lack of coordination between the heart’s upper chambers, or atria, and the lower chambers, known as ventricles. This condition can lead to blood clots, significantly increasing the risk of stroke and heart failure, although many patients experience few to no symptoms.
Peripheral arterial disease affects an estimated 8–12 million adults in the United States. It occurs when arteries in the extremities, particularly the legs, become narrowed due to plaque buildup, resulting in inadequate blood flow. Symptoms may include claudication, or leg pain while walking, among others. While treatments for both PAD and coronary artery disease (CAD) share similarities—such as lifestyle modifications including exercise and healthy eating—individuals with PAD are at a heightened risk of heart attacks, strokes, and amputations. The presence of AFib exacerbates these risks significantly.
“This is a stark reminder that PAD is not just a limb-threatening disease—it’s a marker of widespread atherosclerosis,” said Viet Le, DMSc, MPAS, PA-C, an advanced practice clinician and cardiovascular researcher at Intermountain Health, who served as the principal investigator for the study. “We found that when atrial fibrillation is added to the mix, the risk of heart attack, stroke, and death escalates significantly. Clinicians must screen for AFib in PAD patients and aggressively manage both conditions.”
Call for Enhanced Screening and Treatment
The study’s outcomes underscore the urgent need for improved adherence to screening and treatment protocols for patients with PAD. Despite established guidelines, only 35% of PAD patients currently receive optimal medical therapy, which includes essential measures such as blood pressure control, statin therapy, aspirin usage, and support for smoking cessation.
“Atrial fibrillation should be assessed in all peripheral arterial disease patients, and aggressive preventative treatment should be implemented,” Le emphasized. The connection between these two conditions illustrates the intricate relationship within cardiovascular health and the necessity for comprehensive patient care.
In conclusion, the findings from Intermountain Health serve as a crucial reminder of the complexities surrounding PAD and AFib, and the importance of vigilant monitoring and management to mitigate the risks of serious cardiovascular events. As healthcare providers continue to navigate these challenges, ensuring that patients receive timely screening and appropriate treatment remains a priority for improving health outcomes.
